# Secondary Hyperparathyroidism

Manage secondary hyperparathyroidism by identifying the calcium-phosphate-vitamin D disturbance driving PTH elevation, interpreting serial CKD-MBD markers rather than a single PTH value, and matching PTH-lowering therapy to dialysis status, calcium, phosphate, and progression severity.

**Clinical question:** How should clinicians evaluate and treat secondary hyperparathyroidism in CKD according to dialysis status and mineral abnormalities?

Updated: 2026-09-16T00:37:43.843357+00:00

## What matters in practice
- Interpret PTH together with serial calcium, phosphate, alkaline phosphatase, and vitamin D status; an isolated iPTH value is an unreliable diagnostic discriminator of bone disease in advanced CKD. [6][17]
- For rising or persistently elevated PTH in CKD, first identify modifiable drivers: hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency. [18]
- Do not routinely use calcitriol or vitamin D analogues in nondialysis CKD; reserve them for CKD G4-G5 with severe, progressive hyperparathyroidism. [18]
- In CKD G5D requiring PTH-lowering treatment, calcimimetics, calcitriol, vitamin D analogues, or combinations are therapeutic options; etelcalcetide is supported for adults receiving hemodialysis. [1][18][24]
- Avoid pursuing complete PTH normalization in CKD, because low-turnover bone disease is a competing risk when PTH suppression is excessive. [19][15]

## Confirm the physiologic driver before lowering PTH

Classify the patient by CKD and dialysis status, then interpret PTH as part of a mineral-metabolism pattern.

Obtain serum calcium, phosphate, intact PTH, alkaline phosphatase, and 25-hydroxyvitamin D in CKD-associated PTH elevation; assess creatinine and BUN when distinguishing kidney-related disease from other causes of secondary hyperparathyroidism. Use trends in calcium, phosphate, PTH, and alkaline phosphatase rather than treating an individual PTH measurement as a stand-alone target. [9][17]

In CKD, declining phosphate excretion, impaired renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, and impaired calcium homeostasis drive compensatory PTH secretion. Persistent stimulation produces parathyroid hyperplasia and can progress to renal osteodystrophy, with bone pain and fracture risk. [1][21]

When PTH is gradually rising or remains persistently elevated, specifically review phosphate concentration and dietary phosphate exposure, calcium concentration, and 25-hydroxyvitamin D status before initiating PTH-lowering medication. This sequence distinguishes a potentially reversible biochemical stimulus from severe progressive gland hyperplasia requiring targeted therapy. [18]
- Confirm the PTH assay method used by the laboratory before comparing serial results, because assay methodology affects interpretation. [17]
- Use alkaline phosphatase as a complementary turnover marker; high-turnover and low-turnover renal bone lesions cannot be reliably classified by iPTH alone. [6][15]
- Consider non-CKD causes when kidney dysfunction does not explain the mineral pattern, including vitamin D-deficient rickets, intestinal malabsorption, and pseudohypoparathyroidism. [21]

*Actionable biochemical patterns in secondary hyperparathyroidism. [1][17][18][21]*

| Pattern | Likely interpretation | Immediate next action |
| --- | --- | --- |
| CKD with rising or persistent PTH elevation plus hyperphosphatemia | Phosphate retention is a modifiable stimulus for PTH secretion. [1][18] | Review phosphate intake and phosphate-lowering strategy before escalating PTH-directed therapy. [18] |
| CKD with elevated PTH and hypocalcemia | Reduced calcium availability can drive compensatory PTH secretion. [1][18] | Assess vitamin D status and concurrent phosphate abnormality; correct modifiable contributors. [18] |
| CKD with elevated PTH and low 25-hydroxyvitamin D | Vitamin D deficiency may contribute to secondary hyperparathyroidism. [17][18] | Replete nutritional vitamin D unless hyperphosphatemia is uncontrolled or hypercalcemia is present. [23] |
| Persistent PTH elevation despite correction of phosphate, calcium, and vitamin D factors | Severe or progressive CKD-associated secondary hyperparathyroidism is more likely. [18] | Select therapy according to dialysis status and current calcium-phosphate profile. [18][24] |
| Suppressed or excessively lowered PTH during therapy | Potential low-turnover bone disease is a treatment concern. [15][19] | Reassess the intensity of PTH suppression rather than pursuing PTH normalization. [19] |

## Treat correctable abnormalities first in nondialysis CKD

Routine active vitamin D therapy is not the default strategy for elevated PTH before dialysis.

For adults with CKD G3a-G5 not receiving dialysis, do not routinely prescribe calcitriol or vitamin D analogues solely for elevated PTH. Instead, address hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency when PTH rises progressively or remains elevated. [18]

Reserve calcitriol or a vitamin D analogue for CKD G4-G5 with severe, progressive hyperparathyroidism. This restriction reflects the need to balance PTH suppression against disturbances in calcium and phosphate homeostasis and against excessive PTH suppression. [18][19]

Nutritional vitamin D repletion is appropriate for vitamin D deficiency in CKD, but defer cholecalciferol or ergocalciferol when hyperphosphatemia is uncontrolled or hypercalcemia is present. Follow calcium, phosphate, PTH, creatinine, BUN, and alkaline phosphatase as the biochemical response determines whether management remains correction-focused or requires escalation. [22][23][24]
- Do not infer treatment success from PTH alone; evaluate calcium, phosphate, PTH, and alkaline phosphatase together and over time. [17]
- Avoid a goal of normal-range PTH in nondialysis CKD; current discussion emphasizes prevention of severe progressive disease while avoiding oversuppression. [19]
- If PTH elevation is severe, one cited clinical guideline defines severe secondary hyperparathyroidism as intact PTH greater than 500 pg/mL or whole PTH greater than 300 pg/mL; apply assay-specific interpretation and the patient’s trajectory. [5][17]

*Nondialysis CKD treatment decisions. [18][23][24]*

| Clinical situation | Preferred action | Key monitoring or limitation |
| --- | --- | --- |
| Elevated or rising PTH with low 25-hydroxyvitamin D | Correct vitamin D deficiency with nutritional vitamin D if calcium and phosphate permit. [22][23] | Avoid supplementation during hypercalcemia or until hyperphosphatemia is controlled. [23] |
| Persistent PTH elevation with hyperphosphatemia, hypocalcemia, or high phosphate intake | Correct these modifiable factors before routine active vitamin D treatment. [18] | Use serial calcium, phosphate, PTH, and alkaline phosphatase to assess response. [17] |
| CKD G4-G5 with severe, progressive hyperparathyroidism | Consider calcitriol or a vitamin D analogue. [18] | Monitor calcium and phosphate because therapy can alter both mineral measures. [18][24] |
| Calcitriol titration | Use only within the selected severe/progressive indication. [18][24] | Monitor serum calcium twice weekly during titration. [24] |

## Select PTH-lowering therapy in dialysis from the calcium-phosphate profile

Dialysis-dependent CKD permits calcimimetic, active vitamin D, analogue, or combination therapy when PTH lowering is needed.

For CKD G5D requiring PTH-lowering treatment, acceptable therapeutic classes are calcimimetics, calcitriol, vitamin D analogues, or combinations. Selection should be individualized to the patient’s calcium and phosphate concentrations and the direction of serial PTH, rather than by a single PTH threshold. [18][24]

Etelcalcetide is an intravenous calcimimetic approved for adult patients with CKD receiving hemodialysis and secondary hyperparathyroidism. In a placebo-controlled trial among dialysis patients, etelcalcetide lowered PTH more effectively than placebo. [1][3]

Calcimimetics are a mainstay of secondary hyperparathyroidism treatment in end-stage kidney disease. If active vitamin D treatment is used, monitor calcium, phosphate, creatinine, BUN, and intact PTH; calcium requires twice-weekly monitoring during calcitriol titration. [2][24]
- Use a calcimimetic, calcitriol, vitamin D analogue, or combination only after reviewing concurrent calcium and phosphate abnormalities. [18][24]
- Etelcalcetide is a hemodialysis-specific option; do not extrapolate its labeled population to nondialysis CKD. [1]
- Do not rely on PTH suppression alone as a surrogate for skeletal benefit; renal bone disease spans high-turnover osteitis fibrosa, low-turnover adynamic bone disease, and osteomalacia. [15]

### When to favor ongoing biochemical reassessment

Escalate or de-escalate therapy only after evaluating the full CKD-MBD pattern. CKD-MBD encompasses abnormalities of calcium, phosphate, PTH, vitamin D, and FGF23 metabolism, with consequences that include renal osteodystrophy and vascular calcification; treatment should therefore avoid correcting one marker at the expense of clinically important calcium-phosphate derangement. [23][15]
- Repeat calcium and phosphate when changing vitamin D-based therapy. [24]
- Track alkaline phosphatase with PTH when assessing possible changes in bone turnover, recognizing that no single biomarker definitively classifies renal osteodystrophy. [6][17]

*PTH-lowering options in CKD G5D. [1][2][3][18][24]*

| Option | Appropriate population | Decision-relevant evidence or monitoring |
| --- | --- | --- |
| Calcimimetic | CKD G5D requiring PTH-lowering treatment. [18][24] | Calcimimetics are a mainstay in end-stage kidney disease; use mineral measurements to guide selection and follow-up. [2][18] |
| Etelcalcetide | Adults with CKD on hemodialysis and secondary hyperparathyroidism. [1] | Intravenous calcimimetic; reduced PTH more than placebo in dialysis patients. [3] |
| Calcitriol | CKD G5D requiring PTH lowering; also FDA-indicated for hypocalcemia in chronic renal dialysis. [24] | Monitor calcium, phosphate, creatinine, BUN, and intact PTH; check calcium twice weekly during titration. [24] |
| Vitamin D analogue or combination therapy | CKD G5D requiring PTH lowering. [18][24] | Use when the calcium-phosphate profile and treatment response support vitamin D-based treatment or combination therapy. [18] |

## Use bone and vascular risk to avoid both undertreatment and oversuppression

Persistent secondary hyperparathyroidism contributes to high-turnover bone disease, but low turnover is also clinically consequential.

Sustained PTH excess releases calcium and phosphate from bone and contributes to renal osteodystrophy, bone pain, and fracture risk. CKD-associated fracture risk exceeds that of age-matched controls by more than fourfold, and dialysis patients may have up to an eightfold increased risk. [1][13]

Renal osteodystrophy is a histopathologic term covering high-turnover lesions associated with secondary hyperparathyroidism, low-turnover adynamic bone disease, and osteomalacia. Because iPTH has poor diagnostic accuracy for classifying bone disease, use it as a treatment-monitoring component rather than as a definitive diagnosis of bone turnover state. [6][15]

The relevant tradeoff is not simply elevated versus normal PTH. Avoid complete PTH normalization when treating CKD-associated secondary hyperparathyroidism, particularly if serial results suggest excessive suppression or a low-turnover state. [19][15]
- Investigate new bone pain or fragility fracture in CKD as a possible CKD-MBD complication rather than attributing it automatically to age-related osteoporosis. [1][13][15]
- Treat persistent mineral abnormalities as systemic CKD-MBD because vascular calcification and cardiovascular complications are linked to the syndrome. [15][21][23]
- Use serial biochemical patterns to inform treatment intensity because current diagnostic tools incompletely identify bone and fracture risk in CKD. [6][13]

*Clinical consequences that should alter surveillance and treatment intensity. [1][13][15][21][23]*

| Finding | Clinical implication | Management consequence |
| --- | --- | --- |
| Progressive PTH elevation with mineral abnormalities | Risk of high-turnover renal osteodystrophy increases with sustained secondary hyperparathyroidism. [1][15] | Correct modifiable drivers and use dialysis-status-appropriate PTH-lowering therapy when indicated. [18][24] |
| Very low or markedly suppressed PTH during treatment | Low-turnover adynamic bone disease is part of the renal osteodystrophy spectrum. [15][19] | Reassess treatment intensity; avoid pursuing complete PTH normalization. [19] |
| Bone pain or fracture | Renal osteodystrophy can present with bone pain and increased fracture risk. [1] | Reevaluate calcium, phosphate, PTH, alkaline phosphatase, and vitamin D status; reassess current CKD-MBD therapy. [17][24] |
| Dialysis dependence | Fracture risk may be up to eightfold higher than in age-matched controls. [13] | Maintain active surveillance for biochemical CKD-MBD abnormalities and skeletal complications. [13][17] |

## Monitor treatment by trajectory, adverse mineral effects, and clinical complications

Biochemical response is useful only when interpreted with the medication exposure and evolving CKD stage.

At each treatment change, document the temporal relationship among PTH, calcium, phosphate, alkaline phosphatase, and vitamin D status. A falling PTH accompanied by worsening calcium-phosphate disturbance should prompt reassessment of the therapeutic balance rather than automatic dose escalation. [17][18][24]

For calcitriol, monitor serum calcium, phosphate, creatinine, BUN, and intact PTH; serum calcium should be monitored twice weekly during titration. Hypercalcemia and uncontrolled hyperphosphatemia are reasons not to proceed with nutritional vitamin D supplementation. [23][24]

Escalate concern when PTH remains severe or progressive after correction of phosphate, calcium, dietary phosphate, and vitamin D contributors, or when the patient develops bone pain, fracture, or other CKD-MBD complications. In dialysis patients, this should trigger selection or adjustment among a calcimimetic, calcitriol, vitamin D analogue, or combination regimen. [1][18][21][24]
- Record the dialysis status at every treatment review because etelcalcetide evidence and approval apply to adults on hemodialysis. [1][3]
- Review whether a low calcium value, uncontrolled phosphate elevation, or vitamin D deficiency is the current dominant PTH stimulus before changing medication class. [18]
- Use the same PTH assay method when possible for serial interpretation, and account for assay changes explicitly. [17]

*Monitoring triggers after identifying secondary hyperparathyroidism. [17][18][23][24]*

| Trigger | What to check | What the result changes |
| --- | --- | --- |
| Rising or persistently elevated PTH | Calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D, dietary phosphate exposure, and PTH assay method. [17][18] | Identifies modifiable abnormalities before active vitamin D or calcimimetic escalation. [18] |
| Calcitriol initiation or dose titration | Calcium twice weekly during titration; phosphate, creatinine, BUN, and intact PTH. [24] | Detects adverse mineral effects and informs continuation or adjustment. [24] |
| Hypercalcemia or uncontrolled hyperphosphatemia | Current nutritional vitamin D exposure and calcium-phosphate trend. [23] | Withhold nutritional vitamin D supplementation until the relevant abnormality is addressed. [23] |
| Bone pain, fracture, or concern for altered turnover | PTH, calcium, phosphate, alkaline phosphatase, and vitamin D status. [1][6][17] | Reassesses CKD-MBD activity while recognizing that iPTH alone cannot define bone pathology. [6][15] |

## References
1. [PDF] 208325Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000MedR.pdf
2. Calcimimetic Prescriptions in Fee-for-Service Medicare ... — jamanetwork.com — https://jamanetwork.com/journals/jama-health-forum/fullarticle/2832766
3. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in ... — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2596293
4. Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease — annals.org — https://annals.org/article.aspx?articleid=738088
5. Clinical Practice Guideline for the Management of Chronic Kidney ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1744-9987.12058
6. Diagnostic Accuracy of Biomarkers and Imaging for... - Lippincott — journals.lww.com — https://journals.lww.com/jasn/fulltext/2018/05000/diagnostic_accuracy_of_biomarkers_and_imaging_for.24.aspx
7. Treatment of secondary hyperparathyroidism in non-dialysis CKD — journals.lww.com — https://journals.lww.com/00005884-202306000-00009
8. Real world evaluation of etelcalcetide in the... : Therapeutic Apheresis and Dialysis — journals.lww.com — https://journals.lww.com/01244604-202610000-00006
9. Normocalcaemic primary hyperparathyroidism: An update on ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.14315
10. Baseline characteristics of subjects enrolled in... - Ovid — journals.lww.com — https://journals.lww.com/00005884-201207000-00039
11. Current therapeutic approach of chronic kidney disease‐mineral ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1744-9987.14177
12. Primary hyperparathyroidism and the skeleton - Mosekilde - 2008 ... — anatomypubs.onlinelibrary.wiley.com — https://anatomypubs.onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2007.03162.x
13. Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2468024926028949
14. Management of chronic kidney disease–mineral and bone disorder: Korean working group recommendations — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2211913215000066
15. Chronic Kidney Disease-Mineral and Bone Disorder - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/chronic-kidney-disease-mineral-and-bone-disorder
16. Management of Chronic Kidney Disease Mineral-Bone Disorder - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1548559506001662
17. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10229290
18. Vitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease? - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12049386
19. Vitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10097233
20. Vitamin D and chronic kidney disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4101586
21. Secondary Hyperparathyroidism - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK557822
22. Hyperparathyroidism in Chronic Kidney Disease - Endotext - NCBI — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK278975
23. Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - NCBI — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560742
24. Calcitriol - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK526025

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.